GENE ONLINE|News &
Opinion
Blog

Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial

by Reed Slater
Share To
In a flurry of highs and lows for Biogen this week, the company voluntarily paid a $900 million settlement in a lawsuit brought about by a former employee regarding alleged paid kickbacks for physicians willing to prescribe the company’s multiple sclerosis drugs. At the other end of Biogen’s week, the company reported positive Phase 3 confirmatory trial results from its newest Alzheimer’s drug developed with Eisai, lecanemab, which is set for a regulatory decision in January next year. 

It's free! Log in now to read

LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top